United States · Bill · S
S. 3311 (118th)
American Made Pharmaceuticals Act of 2023
Introduced
15 November 2023
Last action
—
Status
Committee on Banking, Housing, and Urban Affairs. Hearings held. Hearings printed: S.Hrg. 118-655.
Sponsors
—
Subjects
Discovery layer
Source updated
27 May 2026
Summary
American Made Pharmaceuticals Act of 2023 This bill requires the Centers for Medicare & Medicaid Services to conduct a demonstration program that gives preference to domestically manufactured drugs under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP). The program must be conducted in at least eight states and for at least seven years. Applicable drugs include critical drugs that are needed to respond to a public health emergency and that have a vulnerable global supply chain. Preference may take the form of reduced cost-sharing, preferential treatment on formularies, bonus payments, and other specified methods.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in Senate (text)
Introduced in Senate (text)
Introduced in Senate · EN · 15 November 2023
Introduced in Senate (PDF)
Introduced in Senate · EN · 15 November 2023
Introduced in Senate
summary · EN · 15 November 2023
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/118th-congress/senate-bill/3311
- Open data entity: https://api.congress.gov/v3/bill/118/s/3311